These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 9865827)

  • 1. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
    Abramovich CM; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
    Abramovich CM; Prayson RA
    Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
    Ho DM; Hsu CY; Ting LT; Chiang H
    Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
    Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
    Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIB-1 staining index of pediatric meningiomas.
    Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM
    Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry.
    Prayson RA
    Am J Clin Pathol; 1996 Jun; 105(6):719-26. PubMed ID: 8659446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
    Devaprasath A; Chacko G
    Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
    Abramovich CM; Prayson RA
    Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas.
    Hsu DW; Efird JT; Hedley-Whyte ET
    Neuropathol Appl Neurobiol; 1998 Dec; 24(6):441-52. PubMed ID: 9888154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.
    Schiffer D; Ghimenti C; Fiano V
    J Neurooncol; 2005 Jun; 73(2):125-30. PubMed ID: 15981101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
    Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
    Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
    Vankalakunti M; Vasishta RK; Das Radotra B; Khosla VK
    Neuropathology; 2007 Oct; 27(5):407-12. PubMed ID: 18018472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
    Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
    J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
    Abry E; Thomassen IØ; Salvesen ØO; Torp SH
    Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical and malignant meningiomas: a clinicopathological review.
    Mahmood A; Caccamo DV; Tomecek FJ; Malik GM
    Neurosurgery; 1993 Dec; 33(6):955-63. PubMed ID: 8134008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic features predicting recurrence of meningiomas following subtotal resection.
    de la Monte SM; Flickinger J; Linggood RM
    Am J Surg Pathol; 1986 Dec; 10(12):836-43. PubMed ID: 3789250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.